«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年04期

页码:

379-386

栏目:

基础医学

出版日期:

2023-07-10

文章信息/Info

Title:

Pyroptosis-related gene signature predicts the tumor microenvironment and prognosis in neuroblastoma

文章编号:

1006-8147（2023）04-0379-08

作者:

高伟靖; 李龙

天津医科大学基础医学院免疫学系，天津300070

Author(s):

GAO Wei-jing; LI Long

Department of Immunology，School of Basic Medical Sciences，Tianjin Medical University，Tianjin 300070，China

关键词:

焦亡; 神经母细胞瘤; 肿瘤微环境; 预后

Keywords:

pyroptosis; neuroblastoma; tumor microenvironment; prognosis

分类号:

R739.4

DOI:

-

文献标志码:

A

摘要:

目的：研究焦亡相关基因的特征与神经母细胞瘤的肿瘤免疫微环境（TME）的关系以及神经母细胞瘤患者的预后。方法：基因表达数据来自于TCGA、NCBI-GEO和TARGET数据库。ESTIMATE和ssGSEA用于分析TME。LASSO-COX方法用于建立预后模型以量化神经母细胞瘤中焦亡的水平。同时构建了一种名为Risk的新评分方法，并全面地评价Risk评分的有效性。结果：焦亡相关基因在神经母细胞瘤中突变负荷较低（3.35%突变率）。同时，焦亡相关基因的高表达与患者良好的预后相关（HR=0.4036；95%CI：0.2915~0.5587；Log-ranktest，P<0.001）。免疫细胞的浸润程度在焦亡相关基因高表达的患者中更为丰富。多因素Cox分析表明，Risk评分是一种独立的预后因素，可以提高临床预测模型的准确性（曲线下面积均大于0.8）。结合常见的患者临床特征构建的诺模图具有很好的临床预测价值（P<0.001）。低风险患者的免疫细胞浸润也更为丰富，与预后良好相关。结论：焦亡相关基因的特征可以预测神经母细胞瘤患者的免疫微环境，基于焦亡相关基因的表达特征构建的预后模型可很好的预测患者的预后情况。

Abstract:

Objective：The relationship between pyroptosis-related gene signature and the tumor microenvironment（ TME） and the prognosis of patients withneuroblastoma. Methods：Gene expression data were obtained from TCGA，NCBI-GEO and TARGET databases. ESTIMATE and ssGSEA were used to analyze TME. The LASSO-COX method was used to develop a prognostic model to quantify the level of pyroptosis in neuroblastoma. At the same time，a new scoring method called Risk was constructed and the effectiveness of Risk scoring was comprehensively evaluated. Results：Pyroptosis-related genes had low mutational burden in neuroblastoma （ 3.35% mutation rate）. High expression of pyroptosis-related genes indicated good prognosis of patients（ HR=0.403 6；95%CI：0.291 5-0.558 7；Log-rank test， P<0.001）. The infiltration of immune cells was more abundant in patients with high expression of pyroptosis-related genes. Multivariate Cox analysis showed that Risk scoring was an independent prognostic factor that could improve the accuracy of clinical prediction models （ area under curve>0.8）.The Nomograms constructed by combining common clinical characteristics of patients have good clinical predictive value（ P<0.001）. Immune cell infiltration was also more abundant in low-risk patients，which correlated with favorable prognosis. Conclusion：The immune microenvironment of patients with neuroblastoma can be predicted according to the characteristics of pyroptosis-related genes，and the prognostic model constructed based on the expression characteristics of pyroptosis-related genes has good accuracy in predicting the prognosis of patients.

参考文献/References:

[1] MARIS J M，HOGARTY M D，BAGATELL R，et al. Neuroblastoma [J]. Lancet，2007，369（ 9579）：2106-2120.
[2] MATTHAY K K，MARIS J M，SCHLEIERMACHER G，et al. Neu－roblastoma [J]. Nat Rev Dis Primers，2016，2：16078.
[3] NAKAGAWARA A，LI Y，IZUMI H，et al. Neuroblastoma[J]. Jpn J Clin Oncol，2018，48（ 3）：214-241.
[4] PARK J A，CHEUNG N V. Targets and antibody formats for im－munotherapy of neuroblastoma [J]. J Clin Oncol，2020，38（ 16）：1836-1848.
[5] BLAVIER L，YANG R M，DECLERCK Y A. The tumor microenvi－ronment in neuroblastoma：new players，new mechanisms of interac－tion and new perspectives[J]. Cancers（ Basel），2020，12（ 10）：2912.
[6] MELAIU O，CHIERICI M，LUCARINI V，et al. Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma [J]. Nat Commun，2020，11 （1）：5992.
[7] PENTIMALLI F，GRELLI S，DI DANIELE N，et al. Cell death pathologies：targeting death pathways and the immune system for cancer therapy [J]. Genes Immun，2019，20（ 7）：539-554.
[8] ZHANG J Y，ZHOU B，SUN R Y，et al. The metabolite α-KG in－duces GSDMC-dependent pyroptosis through death receptor 6-acti－vated caspase-8 [J]. Cell Res，2021，31（ 9）：980-997.
[9] SHI J，ZHAO Y，WANG K，et al. Cleavage of GSDMD by inflamma－tory caspases determines pyroptotic cell death[J]. Nature，2015，526 （ 7575）：660-665.
[10] ZHANG Z，ZHANG Y，XIA S，et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity[J]. Nature，2020，579 （ 7799）：415-420.
[11] WANG Y，GAO W，SHI X，et al. Chemotherapy drugs induce pyrop－tosis through caspase-3 cleavage of a gasdermin [J].Nature，2017， 547（ 7661）：99-103.
[12] ZHOU Z，HE H，WANG K，et al. Granzyme A from cytotoxic lym－phocytes cleaves GSDMB to trigger pyroptosis in target cells [J]. Sci－ence，2020，368（ 6494）：eaaz7548.
[13] WANG Q，WANG Y，DING J，et al. A bioorthogonal system re－veals antitumour immune function of pyroptosis[J]. Nature，2020， 579（ 7799）：421-426.
[14] BEN-SASSON S Z，HOGG A，HU-LI J，et al. IL-1 enhances expan－sion，effector function，tissue localization，and memory response of antigen-specific CD8 T cells[J]. J Exp Med，2013，210（3）：491-502.
[15] JAIN A，SONG R，WAKELAND E K，et al. T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells[J]. Nat Commun，2018，9（ 1）：3185.
[16] MAN S M，KANNEGANTI T D. Regulation of inflammasome activa－tion[J]. Immunol Rev，2015，265（ 1）：6-21.
[17] TANG R，XU J，ZHANG B，et al. Ferroptosis，necroptosis，and pyrop－tosis in anticancer immunity[J]. J Hematol Oncol，2020，13（ 1）：110.
[18] BETTERS E，LIU Y，KJAELDGAARD A，et al. Analysis of early hu－man neural crest development[J]. Dev Biol，2010，344（2）：578-592.
[19] ZAFAR A，WANG W，LIU G，et al. Molecular targeting therapies for neuroblastoma：progress and challenges [J]. Med Res Rev，2021，41（2）：961-1021.
[20] MORANDI F，SABATINI F，PODEST譆M，et al. Immunotherapeutic strategies for neuroblastoma：present，past and future[J]. Vaccines （ Basel），2021，9（ 1）：43.
[21] PELIZZO G，VESCHI V，MANTELLI M，et al. Microenvironment in neuroblastoma：isolation and characterization of tumor-derived mes－enchymal stromal cells [J]. BMC Cancer，2018，18（ 1）：1176.
[22] VANICHAPOL T，CHUTIPONGTANATE S，ANURATHAPAN U，et al. Immune escape mechanisms and future prospects for im －munothera py in neuroblastoma[J]. Biomed Res Int，2018，2018：1812535.
[23] SUZUKI M，CHEUNG N K. Disialoganglioside GD2 as a therapeutic target for human diseases[J]. Expert Opin Ther Targets，2015，19（3）：349-362.
[24] COOKSON B T，BRENNAN M A. Pro-inflammatory programmed cell death [J]. Trends Microbiol，2001，9（ 3）：113-114.
[25] MAN S M，KARKI R，KANNEGANTI T D. Molecular mechanisms and functions of pyroptosis，inflammatory caspases and inflamma－somes in infectious diseases [J]. Immunol Rev，2017，277（1）：61-75.
[26] ROSENBAUM S R，WILSKI N A，APLIN A E. Fueling the fire：in－flammatory forms of cell death and implications for cancer im－munotherapy[J]. Cancer Discov，2021，11（ 2）：266-281.
[27] FANG Y，TIAN S，PAN Y，et al. Pyroptosis：a new frontier in cancer [J]. Biomed Pharmacother，2020，121：109595.
[28] LUO B，WANG L，GAO W，et al. Using a gene network of pyroptosis to quantify the responses to immunotherapy and prognosis for neu－roblastoma patients [J]. Front Immunol，2022，13：845757.
[29] CRISTESCU R，LEE J，NEBOZHYN M，et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes[J]. Nat Med，2015，21（ 5）：449-456.
[30] GALLUZZI L，BUQU魪A，KEPP O，et al. Immunogenic cell death in cancer and infectious disease[J]. Nat Rev Immunol，2017，17（ 2）：97-111.

相似文献/References:

[1]庞学明,侯爱林,王笑一,等.小儿神经母细胞瘤的MRI诊断[J].天津医科大学学报,2014,20(02):154.
[2]聂红艳,邱艳丽,靳 燕,等.TIAM1蛋白在神经母细胞瘤中的表达及临床意义[J].天津医科大学学报,2019,25(02):143.
　NIE Hong-yan,QIU Yan-li,JIN Yan,et al.Expression and Clinical Significance of TIAM1 in Neuroblastoma[J].Journal of Tianjin Medical University,2019,25(04):143.
[3]杨倩玉,李璇,闫蓓蕾,等.通过生物信息学分析鉴定调控神经母细胞瘤骨髓转移的中枢基因[J].天津医科大学学报,2021,27(03):259.
　YANG Qian-yu,LI Xuan,YAN Bei-lei,et al.Identification of hub genes to regulate neuroblastoma metastasis to bone marrow by bioinformatics analysis[J].Journal of Tianjin Medical University,2021,27(04):259.
[4]高秋雲,孙亚楠,马振毅.GSDMD单域抗体的筛选及功能探究[J].天津医科大学学报,2023,29(06):622.
　GAO Qiu-yun,SUN Ya-nan,MA Zhen-yi.Screening and functional investigation of anti-GSDMD single-domain antibodies[J].Journal of Tianjin Medical University,2023,29(04):622.
[5]缪道玉,于方海 综述,张西波 审校.调节性细胞死亡方式参与阻塞性黄疸引起肝细胞损伤的机制研究[J].天津医科大学学报,2024,30(04):377.[doi:10.20135/j.issn.1006-8147.2024.04.0377]

备注/Memo

备注/Memo:

基金项目: 国家重点研发计划（2018YFC1313000，2018YFC1313002）
作者简介: 高伟靖（1996-），男，硕士在读，研究方向：肿瘤免疫；
通信作者：李龙，E-mail：Long.Li@tmu.edu.cn。

常用功能

更新日期/Last Update: 2023-07-10